Our long-term goal is to develop vaccines and antiviral treatments for Ebolavirus infections. We have developed biologically contained Ebolaviruses that protect mice against challenge with a lethal dose of mouse-adapted Ebolavirus.
In Aim 1, we plan to test the protective efficacy of these Ebolaviruses in guinea pigs and nonhuman primates. Towards drug development, we have established three different highthroughput screening systems that allow screening in BSL-2 containment.
In Aim 2, we propose to conduct high-throughput screening and to optimize lead compounds. The lack of effective preventive or therapeutic treatments for Ebolavirus infections is partly due to the lack of knowledge of cellular genes involved in Ebolavirus replication. Our pilot study demonstrated the potential of siRNA screening approaches to identify such genes;therefore, we plan to conduct siRNA screening of commercially available human siRNA libraries to identify critical genes for the Ebolavirus life cycle (Aim 3). Candidate genes/gene products will then be characterized to elucidate the mechanism(s) by which they interfere with Ebolavirus replication. Studies in Aim 3 may thus suggest novel approaches to the treatment of Ebolavirus infections.
The long-term goal of this research is to develop vaccines and antiviral treatments for Ebolavirus infections. Currently, neither preventative nor therapeutic treatments are available for Ebolavirus infections, making their development an urgent task.
|Le, J; Dam, Q; Schweizer, M et al. (2016) Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37. Eur J Clin Microbiol Infect Dis 35:1441-7|
|Agostoni, Marco; Waters, Christopher M; Montgomery, Beronda L (2016) Regulation of biofilm formation and cellular buoyancy through modulating intracellular cyclic di-GMP levels in engineered cyanobacteria. Biotechnol Bioeng 113:311-9|
|Duckworth, Benjamin P; Wilson, Daniel J; Aldrich, Courtney C (2016) Measurement of Nonribosomal Peptide Synthetase Adenylation Domain Activity Using a Continuous Hydroxylamine Release Assay. Methods Mol Biol 1401:53-61|
|Kuhn, Misty L; Alexander, Evan; Minasov, George et al. (2016) Structure of the Essential Mtb FadD32 Enzyme: A Promising Drug Target for Treating Tuberculosis. ACS Infect Dis 2:579-591|
|Hollands, Andrew; Corriden, Ross; Gysler, Gabriela et al. (2016) Natural Product Anacardic Acid from Cashew Nut Shells Stimulates Neutrophil Extracellular Trap Production and Bactericidal Activity. J Biol Chem 291:13964-73|
|Park, Sung Ryeol; Tripathi, Ashootosh; Wu, Jianfeng et al. (2016) Discovery of cahuitamycins as biofilm inhibitors derived from a convergent biosynthetic pathway. Nat Commun 7:10710|
|Hoang, Ky Van; Chen, Carolyn G; Koopman, Jacob et al. (2016) Identification of Genes Required for Secretion of the Francisella Oxidative Burst-Inhibiting Acid Phosphatase AcpA. Front Microbiol 7:605|
|Lin, Ann E; Beasley, Federico C; Olson, Joshua et al. (2015) Role of Hypoxia Inducible Factor-1Î± (HIF-1Î±) in Innate Defense against Uropathogenic Escherichia coli Infection. PLoS Pathog 11:e1004818|
|Becker, Russell E N; Bubeck Wardenburg, Juliane (2015) Staphylococcus aureus and the skin: a longstanding and complex interaction. Skinmed 13:111-9; quiz 120|
|Lopera, Juan G; Falendysz, Elizabeth A; Rocke, Tonie E et al. (2015) Attenuation of monkeypox virus by deletion of genomic regions. Virology 475:129-38|
Showing the most recent 10 out of 505 publications